These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 611915)

  • 1. [Pharmacokinetic behavior of clofibrate in patients with kidney insufficiency].
    Hartlapp J; Kürten J; Klehr U; Gugler R
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1709-11. PubMed ID: 611915
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics of buflomedil after intravenous administration in patients with chronic renal failure.
    Rey E; d'Athis P; Richard MO; Fillastre JP; Olive G
    Int J Clin Pharmacol Ther Toxicol; 1984 Dec; 22(12):648-52. PubMed ID: 6526539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of clofibrate in patients with renal insufficiency.
    Viikari J; Anttila M; Kasanen A
    Int J Clin Pharmacol Ther Toxicol; 1983 Feb; 21(2):77-80. PubMed ID: 6840929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of clofibrate and chlorophenoxy isobutyric aicd. I. Cross-over studies on human volunteers.
    Männistö PT; Tuomisto J; Jounela A; Penttilä O
    Acta Pharmacol Toxicol (Copenh); 1975 Apr; 36(4):353-65. PubMed ID: 1093358
    [No Abstract]   [Full Text] [Related]  

  • 5. Clofibrate disposition in renal failure and acute and chronic liver disease.
    Gugler R; Kürten JW; Jensen CJ; Klehr U; Hartlapp J
    Eur J Clin Pharmacol; 1979 Jun; 15(5):341-7. PubMed ID: 456406
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacokinetic aspects of digoxin in patients with terminal renal failure. I. Off dialysis.
    van der Vijgh WJ
    Int J Clin Pharmacol Biopharm; 1977 Jun; 15(6):249-54. PubMed ID: 881276
    [No Abstract]   [Full Text] [Related]  

  • 7. Plasma half disappearance time and metabolic clearance rate of exogenous LH-RH in patients with chronic renal failure.
    Gryczyńska M; Kosowicz J; Czekalski S
    Mater Med Pol; 1980; 12(1-2):124-8. PubMed ID: 7035762
    [No Abstract]   [Full Text] [Related]  

  • 8. Clofibrate and clofibric acid: comparison of the metabolic disposition in rats and dogs.
    Cayen MN; Ferdinandi ES; Greselin E; Robinson WT; Dvornik D
    J Pharmacol Exp Ther; 1977 Jan; 200(1):33-43. PubMed ID: 833760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacokinetics of hydroxyethyl starch in kidney failure].
    Köhler H; Kirch W; Vogt J; Höffler D
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1676-8. PubMed ID: 77105
    [No Abstract]   [Full Text] [Related]  

  • 10. Plasma half-life of clofibric acid in renal failure.
    Faed EM; McQueen EG
    Br J Clin Pharmacol; 1979 Apr; 7(4):407-10. PubMed ID: 444361
    [No Abstract]   [Full Text] [Related]  

  • 11. Disposition pharmacokinetics of bezafibrate in man.
    Abshagen U; Bablok W; Koch K; Lang PD; Schmidt HA; Senn M; Stork H
    Eur J Clin Pharmacol; 1979 Aug; 16(1):31-8. PubMed ID: 499297
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacokinetic aspects of digoxin in patients with terminal renal failure. II. On hemodialysis.
    van der Vijgh WJ
    Int J Clin Pharmacol Biopharm; 1977 Jun; 15(6):255-9. PubMed ID: 881277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antibacterial chemotherapy in renal failure].
    Briedigkeit H
    Z Urol Nephrol; 1983 May; 76(5):349-52. PubMed ID: 6880421
    [No Abstract]   [Full Text] [Related]  

  • 14. Changes in blood thiamphenicol levels in renal failure.
    Traeger J; Moskovchenko J; Monier JC; Zech P
    Postgrad Med J; 1974 Oct; 50 Suppl 5():39-40. PubMed ID: 4470816
    [No Abstract]   [Full Text] [Related]  

  • 15. [Pharmacokinetic study in man of hypolipemic agents derived from clofibric acid after single and repeated administration].
    Cailleux A; Allain P; Tadei A
    Therapie; 1976; 31(5):637-45. PubMed ID: 1013956
    [No Abstract]   [Full Text] [Related]  

  • 16. [Characteristics of the pharmacokinetics of drugs in renal failure].
    Nadzhimutdinov KN; Krakovskiĭ ME
    Farmakol Toksikol; 1985; 48(5):109-13. PubMed ID: 3908139
    [No Abstract]   [Full Text] [Related]  

  • 17. Glucuronic acid conjugates of clofibrate: four isomeric structures.
    Hignite CE; Tschanz C; Lemons S; Wiese H; Azarnoff DL; Huffman DH
    Life Sci; 1981 May; 28(18):2077-81. PubMed ID: 7242269
    [No Abstract]   [Full Text] [Related]  

  • 18. [Common errors in pharmacotherapy of patients with chronic kidney disease].
    Maus S; Keller F
    MMW Fortschr Med; 2011 Apr; 153(16):39-42. PubMed ID: 22329322
    [No Abstract]   [Full Text] [Related]  

  • 19. [A quantitative gaschromatographic method for the determination of p-chlorophenoxyisobutyric acid (clofibrinic acid) in human plasma (author's transl)].
    Häselbarth V
    Arzneimittelforschung; 1976; 26(11):2076-80. PubMed ID: 1037251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of hydroxy-DL-proline-2-(14)C in the investigation of hydroxyproline metabolism in normal subjects and in patients with renal insufficiency.
    Hart W; van den Hamer CJ; van der Sluys Veer J
    Clin Nephrol; 1976 Sep; 6(3):379-87. PubMed ID: 991465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.